Pharmaceutical has ended its collaboration with Cell Genesys
related to GVAX
immunotherapy for prostate cancer
. After two separate Phase III trials were stopped short, the firms along with wholly owned subsidiary Millennium: The Takeda Oncology Company decided to suspend development of the drug.
Under the development and commercialization deal between the companies, Takeda will return all commercial rights to GVAX immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments in connection with the phasing out of the remaining clinical development activities.
Cell Genesys is also evaluating GVAX cancer immunotherapy in leukemia, pancreatic cancer, and lung cancer.